Patents Examined by Anand U Desai
-
Patent number: 11752159Abstract: The present invention includes a method of suppressing systemic immune response in a subject, the method comprising topically administering a pharmaceutically effective amount of a vitamin D analog to a subject in need thereof. The present invention further includes a method of treating an autoimmune disease in a subject, the method comprising topically administering a pharmaceutically effective amount of a vitamin D analog to a subject in need thereof.Type: GrantFiled: April 12, 2021Date of Patent: September 12, 2023Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventor: Taku Kambayashi
-
Patent number: 11730859Abstract: The method for decellularization of kidney tissue according to the present invention, the decellularized material produced through the method, and a bioink comprising the decellularized material have the effect of maximizing the effect of kidney treatment by maximizing the content of components specialized for kidney treatment such as the collecting duct and renal tubule of the kidney.Type: GrantFiled: September 15, 2020Date of Patent: August 22, 2023Assignee: POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATIONInventors: Dong-Woo Cho, Jae Yun Kim, Jae Yeon Lee
-
Patent number: 11717548Abstract: The present disclosure relates to synthetic oncolytic viruses comprising a lipid nanoparticle comprising one or more types of lipid and a self-amplifying replicon RNA comprising a sequence that encodes an immunomodulatory molecule.Type: GrantFiled: January 10, 2020Date of Patent: August 8, 2023Assignees: Massachusetts Institute of Technology, Ohio State Innovation FoundationInventors: Darrell J. Irvine, Karl Dane Wittrup, Ron Weiss, Yingzhong Li, Noor Momin, Yizhou Dong
-
Patent number: 11718656Abstract: The disclosure provides inducible caspase polypeptides, compositions comprising inducible caspase polypeptides and sequences encoding the same, cells modified to express the polypeptides and compositions of the disclosure, as well as methods of making and methods of using same for adoptive cell therapy.Type: GrantFiled: June 2, 2022Date of Patent: August 8, 2023Assignee: Poseida Therapeutics, Inc.Inventors: Eric M. Ostertag, Devon Shedlock
-
Patent number: 11713359Abstract: The present invention provides a nanodisc with a membrane scaffold protein. The nanodisc includes a membrane scaffold protein, a telodendrimer and a lipid. The membrane scaffold protein can be apolipoprotein. The telodendrimer has the general formula PEG-L-D-(R)n, wherein D is a dendritic polymer; L is a bond or a linker linked to the focal point group of the dendritic polymer; each PEG is a poly(ethylene glycol) polymer, each R is and end group of the dendritic polymer, or and end group with a covalently bound hydrophobic group, hydrophilic group, amphiphilic compound, or drug; and subscript n is an integer from 2 to 20. Cell free methods of making the nanodiscs are also provided.Type: GrantFiled: May 5, 2021Date of Patent: August 1, 2023Assignee: LAWRENCE LIVERMORE NATIONAL SECURITY, LLCInventors: Juntao Luo, Wei He, Kit S. Lam, Paul Henderson, Matthew A. Coleman
-
Patent number: 11708589Abstract: Provided herein is a non-naturally occurring microbial organism having a 1,3-butanediol (1,3-BDO) pathway and comprising at least one exogenous nucleic acid encoding a 1,3-BDO pathway enzyme expressed in a sufficient amount to produce 1,3-BDO. In some embodiments, the pathway includes reducing equivalents from CO or hydrogen. In certain embodiments, a 1,3-BDO pathway proceeds by way of central metabolites pyruvate, succinate or alpha-ketoglutarate. Also provided herein is a method for producing 1,3-BDO, includes culturing such microbial organisms under conditions and for a sufficient period of time to produce 1,3-BDO.Type: GrantFiled: June 5, 2020Date of Patent: July 25, 2023Assignee: Genomatica Inc.Inventors: Anthony P. Burgard, Mark J. Burk, Robin E. Osterhout, Jun Sun, Priti Pharkya
-
Patent number: 11703510Abstract: The present invention relates to methods and products associated with in vivo enzyme profiling. In particular, the invention relates to methods of in vivo processing of exogenous molecules followed by detection of signature molecules as representative of the presence of active enzymes associated with diseases or conditions. The invention also relates to products, kits, and databases for use in the methods of the invention.Type: GrantFiled: November 6, 2020Date of Patent: July 18, 2023Assignee: Massachusetts Institute of TechnologyInventors: Sangeeta N. Bhatia, Geoffrey A. von Maltzahn, Gabriel A. Kwong
-
Patent number: 11692015Abstract: The present invention relates to a modified fibroin including a domain sequence represented by Formula 1: [(A)nmotif-REP]m or Formula 2: [(A)nmotif-REP]m?(A)n motif, in which the domain sequence has an amino acid sequence with a reduced content of a glutamine residue equivalent to an amino acid in which one or a plurality of glutamine residues in REP are deleted or substituted with other amino acid residues, as compared with a naturally occurring fibroin.Type: GrantFiled: July 25, 2018Date of Patent: July 4, 2023Assignees: Spiber Inc., RikenInventors: Keisuke Morita, Yunosuke Abe, Takehisa Maekawa, Koichi Kotaka, Junichi Sugahara, Keiji Numata
-
Patent number: 11673913Abstract: Tetrameric N-terminally acetylated ?-synuclein is prepared by transforming an expression system with an expression vector encoding ?-synuclein, wherein the expression system expresses a native NatB acetylase complex or ortholog thereof and/or wherein an exogenous NatB acetylase complex or ortholog thereof is co-expressed in the expression system, inducing protein expression in the transformed expression system, lysing cells in the transformed expression system to produce a cell lysate, performing salt precipitation of the cell lysate, recovering tetrameric N-terminally acetylated ?-synuclein by centrifugation, and purifying the tetrameric N-terminally acetylated ?-synuclein. Compositions comprising the same and methods for identifying compounds that stabilize natively folded tetrameric ?-synuclein are also provided.Type: GrantFiled: May 10, 2019Date of Patent: June 13, 2023Assignee: Virginia Commonwealth UniversityInventors: Heather R. Lucas, Ricardo D. Fernandez
-
Patent number: 11667917Abstract: The present invention relates to a composition for genome editing using a CRISPR/Cpf1 system and a use thereof and, more particularly, to a composition for genome editing comprising: a CRISPR RNA (crRNA) including a guide sequence capable of hybridizing with a target nucleotide sequence, and a uridine repeat sequence connected to the 3?-end of the guide sequence, or a DNA encoding the same; and a Cpf1 protein or a DNA encoding the same, a method for genome editing using the same, a method for construction of a genetically modified organism, and a genetically modified organism. The present invention can increase an indel efficiency and decrease off-target activity in genome editing of eukaryotic cells using the CRIPSPR/Cpf1 system and thus can easily construct a genetically modified cell or genetically modified animal or plant having a desired gene inserted thereinto (knock-in) or deleted therefrom (knock-out).Type: GrantFiled: November 21, 2018Date of Patent: June 6, 2023Assignee: GENKORE CO. LTD.Inventors: Yong Sam Kim, Jeong Heon Ko, Jeong Mi Lee, Su Bin Moon
-
Patent number: 11661593Abstract: Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.Type: GrantFiled: December 16, 2014Date of Patent: May 30, 2023Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Meinhard Hasslacher, Christian Fiedler, Christa Mayer, Artur Mitterer
-
Patent number: 11655279Abstract: The present invention relates to a method for producing an active form of a long-acting insulin analogue derivative, in which the amino acid at position 22 of the insulin B-chain is substituted from arginine (Arg) to lysine (Lys), so that the insulin analogue can be converted to an active form without cleavage of the B-chain even when it is reacted with clostripain. In a conventional method of converting pro-insulin to an active form by use of trypsin, an albumin binding domain is cleaved, making it difficult to convert the long-acting insulin analogue derivative to an active form. The production method according to the present invention overcomes this difficulty, and thus it can be effectively used for the production of a long-acting therapeutic agent for treatment of diabetes.Type: GrantFiled: July 19, 2019Date of Patent: May 23, 2023Assignee: DAEWOONG PHARMACEUTICAL CO., LTD.Inventors: Kyong Hoon Ahn, Seonkyeong Jeong, Chaeha Yoon
-
Patent number: 11655477Abstract: The present disclosure includes genetically engineered, non-pathogenic Streptomyces bacterium with exogenous, non-native Thaxtomin A (ThxA) biosynthetic gene clusters conferring the genetically engineered, non-pathogenic Streptomyces bacterium with the ability to produce thaxtomin A. Also included are methods of providing thaxtomin producing capability in non-native Streptomyces bacterial strains, methods of producing thaxtomin compounds with the genetically engineered Streptomyces bacteria of the present disclosure, and methods of producing thaxtomin compounds and nitro-tryptophan analogs, and fluorinated thaxtomin compounds, analogs, and intermediates with the genetically engineered Streptomyces bacteria of the present disclosure.Type: GrantFiled: May 23, 2018Date of Patent: May 23, 2023Assignee: University of Florida Research Foundation, IncorporatedInventors: Rosemary Loria, Yucheng Zhang, Yousong Ding, Guangde Jiang
-
Patent number: 11656232Abstract: The present invention provides novel allergens isolated from grass carp Ctenopharyngodon idella, recombinant or modified polypeptides comprising such allergens, nucleic acids encoding the polypeptides as well as related compositions. Also provided are methods and kits for diagnosing fish allergy.Type: GrantFiled: September 30, 2019Date of Patent: May 23, 2023Assignee: The Chinese University of Hong KongInventors: Sze Yin Agnes Leung, Ting Fan Leung, Yat Hin Nicki Leung, Yee Yan Christine Wai
-
Patent number: 11648279Abstract: Provided are a composition for cell transplant and a method for cell transplant, both of which enable a myocardial tissue to favorably retain cardiac myocytes and/or cardiac progenitors and can improve the persistence and proliferation of transplanted cells. The composition for cell transplant of the present invention is a composition for cell transplant, containing cells and an aqueous solution containing a protein (A), the cells including a cardiac myocyte and/or a cardiac progenitor, the protein (A) having a degree of hydrophobicity of 0.2 to 1.Type: GrantFiled: May 9, 2019Date of Patent: May 16, 2023Assignees: KYOTO UNIVERSITY, SANYO CHEMICAL INDUSTRIES, LTD.Inventors: Yoshinori Yoshida, Takeshi Hatani, Ryosuke Suzuki, Shingo Kawabata
-
Patent number: 11649445Abstract: Provided herein are compositions with enhanced protein specific activity, protein combinations and methods for the preparation thereof.Type: GrantFiled: September 7, 2021Date of Patent: May 16, 2023Assignee: CLARA FOODS CO.Inventors: Halle Redfearn, Harshal Kshirsagar, Kritika Mahadevan, Alexandre Chapeaux, Wesley Rutherford-Jenkins, Joel Andrew Kreps, Isha Joshi
-
Patent number: 11643642Abstract: The present invention provides engineered penicillin G acylase (PGA) enzymes, polynucleotides encoding the enzymes, compositions comprising the enzymes, and methods of using the engineered PGA enzymes.Type: GrantFiled: May 23, 2018Date of Patent: May 9, 2023Assignee: Codexis, Inc.Inventors: Rama Voladri, Christopher Michael Micklitsch, Oscar Alvizo, Jovana Nazor, Da Duan, Judy Victoria Antonio Viduya, Stephan Jenne, Chihui An, Keith Allen Canada, Paul N. Devine, Iman Farasat, Anna Fryszkowska, Katrina W. Lexa, Robert Kevin Orr
-
Patent number: 11643449Abstract: The disclosure pertains to the field of molecular means capable of binding calcium, in particular peptides which are calcium chelators, appropriate for use in vitro or in vivo and preferably capable of targeting specific cellular compartments. Polypeptide comprising a first calcium-binding domain, a peptide linker and a second calcium binding domain, wherein the first and second binding domains are linked through the peptide linker, and wherein: the first calcium-binding domain and the second calcium binding domain each comprise at least one calcium-binding site derived from a EF-hand motif; and, the first calcium-binding domain and the second calcium binding domain differ in at least one calcium-binding site.Type: GrantFiled: November 2, 2018Date of Patent: May 9, 2023Assignee: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)Inventors: Xavier Nicol, Oriol Ros Torres
-
Patent number: 11628208Abstract: A method for producing at least one microneedle containing a vaccine for transdermal delivery of the vaccine to a patient includes preparing microparticles or nanoparticles of encapsulated vaccine by preparing a solution comprising a vaccine antigen and a biocompatible polymer matrix; and spray drying the solution to form the microparticles or nanoparticles. The method includes the further steps of preparing a film composition including at least one pre-polymer solution; preparing a suspension comprising the microparticles or nanoparticles and the film composition; loading the suspension into a 3D printer; printing, via the 3D printer, at least one microneedle made from the suspension; and, converting the pre-polymer solution into a cross-linked biopolymer by exposing the at least one microneedle to UV light. Also disclosed are microneedles containing a vaccine for transdermal delivery.Type: GrantFiled: November 30, 2020Date of Patent: April 18, 2023Assignee: THE CORPORATION OF MERCER UNIVERSITYInventor: Martin J. D'Souza
-
Patent number: 11613744Abstract: Provided are u-PA polypeptides and fusion proteins containing the u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.Type: GrantFiled: January 3, 2020Date of Patent: March 28, 2023Assignee: Vertex Pharmaceuticals IncorporatedInventors: Edwin L. Madison, Christopher Thanos, Vanessa Soros, Mikhail Popkov, Kimberly Tipton, Matthew John Traylor, Eric Steven Furfine, Jeffrey Charles Way